Cargando…

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention

Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and additional risk factors in the pivotal REDUCE-IT trial. Sinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Toth, Peter P., Ferrières, Jean, Waters, Max, Mortensen, Martin Bødtker, Lan, Nick S. R., Wong, Nathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501481/
https://www.ncbi.nlm.nih.gov/pubmed/37719970
http://dx.doi.org/10.3389/fcvm.2023.1220017
_version_ 1785106119842070528
author Toth, Peter P.
Ferrières, Jean
Waters, Max
Mortensen, Martin Bødtker
Lan, Nick S. R.
Wong, Nathan D.
author_facet Toth, Peter P.
Ferrières, Jean
Waters, Max
Mortensen, Martin Bødtker
Lan, Nick S. R.
Wong, Nathan D.
author_sort Toth, Peter P.
collection PubMed
description Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and additional risk factors in the pivotal REDUCE-IT trial. Since the publication of REDUCE-IT, there has been global interest in determining IPE eligibility in different patient populations, the proportion of patients who may benefit from IPE, and cost effectiveness of IPE in primary and secondary prevention settings. The aim of this review is to summarize information from eligibility and cost effectiveness studies of IPE to date. A total of sixteen studies were reviewed, involving 2,068,111 patients in the primary or secondary prevention settings worldwide. Up to forty-five percent of patients were eligible for IPE, depending on the selection criteria used (ie, REDUCE-IT criteria, US Food and Drug Administration label, Health Canada label, practice guidelines) and the population studied. Overall, eight cost-effectiveness studies across the United States, Canada, Germany, Israel, and Australia were included in this review and findings indicated that IPE is particularly cost effective in patients with established CVD.
format Online
Article
Text
id pubmed-10501481
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105014812023-09-15 Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention Toth, Peter P. Ferrières, Jean Waters, Max Mortensen, Martin Bødtker Lan, Nick S. R. Wong, Nathan D. Front Cardiovasc Med Cardiovascular Medicine Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and additional risk factors in the pivotal REDUCE-IT trial. Since the publication of REDUCE-IT, there has been global interest in determining IPE eligibility in different patient populations, the proportion of patients who may benefit from IPE, and cost effectiveness of IPE in primary and secondary prevention settings. The aim of this review is to summarize information from eligibility and cost effectiveness studies of IPE to date. A total of sixteen studies were reviewed, involving 2,068,111 patients in the primary or secondary prevention settings worldwide. Up to forty-five percent of patients were eligible for IPE, depending on the selection criteria used (ie, REDUCE-IT criteria, US Food and Drug Administration label, Health Canada label, practice guidelines) and the population studied. Overall, eight cost-effectiveness studies across the United States, Canada, Germany, Israel, and Australia were included in this review and findings indicated that IPE is particularly cost effective in patients with established CVD. Frontiers Media S.A. 2023-08-31 /pmc/articles/PMC10501481/ /pubmed/37719970 http://dx.doi.org/10.3389/fcvm.2023.1220017 Text en © 2023 Toth, Ferrières, Waters, Mortensen, Lan and Wong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Toth, Peter P.
Ferrières, Jean
Waters, Max
Mortensen, Martin Bødtker
Lan, Nick S. R.
Wong, Nathan D.
Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
title Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
title_full Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
title_fullStr Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
title_full_unstemmed Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
title_short Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
title_sort global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501481/
https://www.ncbi.nlm.nih.gov/pubmed/37719970
http://dx.doi.org/10.3389/fcvm.2023.1220017
work_keys_str_mv AT tothpeterp globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention
AT ferrieresjean globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention
AT watersmax globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention
AT mortensenmartinbødtker globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention
AT lannicksr globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention
AT wongnathand globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention